

General Information

CONFERENCE PRESIDENT

Professor Gregor B. E. Jemec
Department of Dermatology, Zealand University
Hospital, Roskilde; Health Sciences Faculty,
University of Copenhagen, Denmark

VENUE

DGI-byen
Tietgensgade 65
1704 Copenhagen V
Denmark

LEGAL ORGANISER & PCO

MCI Deutschland GmbH
MCI | Berlin Office
Markgrafenstr. 56, 10117 Berlin, Germany
P: +49 30 204590
F: +49 30 2045950
E: ehsf@mci-group.com

OFFICIAL LANGUAGE

The conference language is English.

REGISTRATION

The registration for EHSF 2017 is open! You can either register online or download the registration form provided on the website (www.ehsf2017.com). Early registration is encouraged to benefit from discounted rates:

Conference Delegate	Early Fee until 16/01/2017	Late Fee from 17/01/2017
Member of EHSF*	€ 395	€ 445
Member of EADV/AAD*	€ 395	€ 445
Non-member	€ 445	€ 495
Nurse/Allied health professional*	€ 195	€ 295
Junior doctor*/ PhD student*	€ 145	€ 295
Day ticket	€ 245	€ 245

* An appropriate proof of status is required. Participants are requested to register in advance by completing and submitting the registration form online with appropriate fees.

KEY DATES TO REMEMBER

Early registration deadline: 16 January 2017

Abstract submission deadline: 2 January 2017

ADDRESSING THE TOUGHEST HEALTH CHALLENGES IN DERMATOLOGY TAKES ALL OF US.

That's why we collaborate each day with physicians, academics, clinical experts, peers, and others. Together, we can truly make a difference for patients.

As a global biopharmaceutical company, we use our expertise, knowledge, resources, and passion to impact patients around the world.

At AbbVie, our solutions start with science but end with a new way forward. For all of us.

LEARN MORE AT OUR **BOOTH** AND **SCIENTIFIC SYMPOSIUM.**



PEOPLE. PASSION.
POSSIBILITIES.

©2016 AbbVie Inc. GBL/HHS/1116/1375 December 2016



abbvie

www.ehsf2017.com



CALL FOR
ABSTRACTS

6TH CONFERENCE OF THE

EHSF 2017

European Hidradenitis Suppurativa Foundation e.V.

8-10 FEBRUARY
COPENHAGEN, DENMARK

Welcoming Address

DEAR COLLEAGUES,

Welcome to the 6th Conference of the European Hidradenitis Suppurativa Foundation. Hidradenitis suppurativa has never attracted so much attention before and the need for exchange of information and opinion has never been greater – which is good news for both – patients and researchers. The conference will support the flow of new ideas in the field, by bringing together the key stakeholders in a programme that we hope will offer something to both patients and researchers in academia as well as industry.

There is much catching up to do with Hidradenitis, but although many other fields have an advantage they have gained over time, we have the advantage of starting in the current golden era of new biomedical research techniques. The catching up may therefore prove to be faster and more effective than one may fear. Another advantage offered by the conference is the facility for collaboration, which is even greater in Hidradenitis than in many other fields because of the many opportunities for even basic discoveries and an inclusive community. We learn and develop from being inclusive rather than divisive.

Finally, we hope that the better understanding of the disease will also open the way for a broader collaboration with the non-dermatological community, based on the unique biological characteristics of Hidradenitis.

We invite you to join us for a memorable conference here in Copenhagen from 8th to 10th February.

On behalf of the Organising and Scientific Programme Committees

Gregor B. E. Jemec
President, 6th EHSF Conference

Main Topics & Call for Abstracts

MAIN TOPICS

- 🌀 Epidemiology and registries
- 🌀 Adjuvant therapy
Focus: Handicap
- 🌀 Medical treatment
Focus: Comorbidities
- 🌀 Genetics
Focus: Syndromic Hidradenitis Suppurativa
- 🌀 Immunology
Focus: Clinical classification
- 🌀 Other treatments, microbiology, innovative research
Focus: Outcome measures

CALL FOR ABSTRACTS

Abstract Submission Deadline: 2 January 2017

You are cordially invited to submit an abstracts for consideration and inclusion in the programme. Please note only electronic submission will be accepted. Detailed instructions can be found on the conference homepage.

Abstract Submission Guidelines

- 🌀 Abstract text is limited to 3,000 characters
- 🌀 Abstracts must be submitted in British English
- 🌀 All abstracts must contain original work that has not been published or presented identically on previous occasions
- 🌀 Indicate the preferred type of presentation (oral or poster) and choose a topic from the drop-down list
- 🌀 The title should be as brief as possible but long enough to indicate clearly the nature of the study. Abbreviations must not be used in the title
- 🌀 Up to 1 table and 1 graphic/picture can be used
- 🌀 Please check spelling and grammar carefully.
All abstracts will be published as submitted
- 🌀 Use generic names. Commercial drug names may not be used

Registration

The acceptance of your abstract does not include conference registration. In order to ensure that your abstract will be reviewed at least one author (the first or the presenting author) is therefore kindly asked to register for the conference.

Committees

SCIENTIFIC COMMITTEE

A. D. Cohen (Israel)
B. Danby (USA)
V. Del Marmol (Belgium)
N. Desai (United Kingdom)
D. N. Dufour (Denmark)
L. Emtestam (Sweden)
E. Giannellos-Bourboulis (Greece)
P. Guillem (France)
W. Gulliver (Canada)
I. Hamzavi (USA)
B. Horváth (Netherlands)
J. Ingram (United Kingdom)
D. Ioannides (Greece)
A. B. Kimball (USA)
O. Join-Lambert (France)
Q. Ju (China)
I. Juhasz (Hungary)
L. Kemény (Hungary)
B. Kirby (Ireland)
I. Kurokawa (Japan)
L. Margesson (USA)
A. Martorell-Calatayud (Spain)
A. Massa (Portugal)
L. Matusiak (Poland)
A. Nassif (France)
R. Paus (United Kingdom)
M. Podda (Germany)
D. Presser (Germany)
E. Prens (Netherlands)
J. P. Ramirez (Spain)
J. Revuz (France)
M. Romanelli (Italy)
R. Sabat (Germany)
K. Sartorius (Sweden)
S. Schneider-Burrus (Germany)
J. Sciacca Kirby (USA)
R. Gary Sibbald (Canada)
R. Sinclair (Australia)
D. H. Suh (Korea)
J. Szepietowski (Poland)
T. Tzellos (Norway)
H. H. Van Der Zee (Netherlands)
B. Wang (China)

P. Wolkenstein (France)
X. Wortsman (Chile)
C. C. Zouboulis (Germany)

ORGANISING COMMITTEE

S. Esmann (Denmark)
G. B. E. Jemec (Denmark)
H. C. Ring (Denmark)
P. Theut Riis (Denmark)
D. M. Saunte (Denmark)
L. Thorlacius (Denmark)
T. Tzellos (Norway)
H. van der Zee (Netherlands)